<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00726999</url>
  </required_header>
  <id_info>
    <org_study_id>06/71,GC 138</org_study_id>
    <nct_id>NCT00726999</nct_id>
  </id_info>
  <brief_title>Perioperative Use of Gabapentin To Decrease Narcotic Requirements in Spinal Fusion</brief_title>
  <official_title>Perioperative Use of Gabapentin To Decrease Opioid Requirements in Pediatric Spinal Fusion Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical College of Wisconsin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Children's Hospital and Health System Foundation, Wisconsin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical College of Wisconsin</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Blinded study using oral gabapentin in load pre-operative (15mg/kg) and maintenance 5mg/kg
      three times a day (TID) for 5 days or discharge, Patient Controlled Analgesia (PCA) morphine
      and placebo group with similar pills, also PCA morphine. The goal is to measure morphine
      usage and incidence of morphine side effects (pruritis, days foley, days to first stool,
      sedation, pain scores, PCA use).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Healthy, American Society of Anesthesia (ASA) 1-2 Idiopathic Scoliosis patients for spinal
      fusion.

      Blinded, drug only known by hospital pharmacist. Study group 1- Gabapentin 15mg/kg with
      premed, 5/kg TID for 5 days of discharge, standard PCA morphine with dose and basal Study
      Group 2- Capsules resembling neurontin, with standard PCA morphine

      No remifentanil, clonidine, ketamine

      N=60 First patient enrolled 6/06 Last patient enrolled 7/15/08
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Amount of Morphine Consumed (mg/kg/hr)</measure>
    <time_frame>PARU (Postanesthesia Recovery Unit - participants typically remain in PARU for 1 hour)</time_frame>
    <description>Patients are taken to the PARU immediately after surgery, and typically remain for a period of 1 hour.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Amount of Morphine Consumed (mg/kg/hr)</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Amount of Morphine Consumed (mg/kg/hr)</measure>
    <time_frame>Day 2</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Side Effect Occurrence</measure>
    <time_frame>First 10 days after surgery</time_frame>
    <description>The number of episodes of/occurrence of side effects was monitored in both groups.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">63</enrollment>
  <condition>Postoperative Pain</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Gabapentin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Comparator -- pill matched in appearance to gabapentin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gabapentin</intervention_name>
    <description>oral gabapentin in load pre-op (15mg/kg) and maintenance 5mg/kg TID for 5 days or discharge</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Neurontin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine</intervention_name>
    <description>Administered as needed</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ASA 1-2, Idiopathic Scoliosis

        Exclusion Criteria:

          -  ASA 3 or greater

          -  Neuromuscular scoliosis

          -  On narcotics baseline
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>9 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lynn M Rusy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical College of Wisconsin</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>January 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 30, 2008</study_first_submitted>
  <study_first_submitted_qc>July 31, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 1, 2008</study_first_posted>
  <results_first_submitted>August 19, 2010</results_first_submitted>
  <results_first_submitted_qc>December 28, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 30, 2010</results_first_posted>
  <last_update_submitted>January 3, 2011</last_update_submitted>
  <last_update_submitted_qc>January 3, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 4, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr. Lynn M. Rusy</name_title>
    <organization>Medical College of Wisconsin Anesthesia Department</organization>
  </responsible_party>
  <keyword>Gabapentin</keyword>
  <keyword>Pediatric Spinal Fusion</keyword>
  <keyword>Narcotic Use</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Morphine</mesh_term>
    <mesh_term>Narcotics</mesh_term>
    <mesh_term>Gabapentin</mesh_term>
    <mesh_term>gamma-Aminobutyric Acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Gabapentin/Morphine</title>
          <description>Gabapentin - group received gabapentin 3 times daily 5 mg/kg/dose. *Both groups received Morphine as needed.</description>
        </group>
        <group group_id="P2">
          <title>Placebo/Morphine</title>
          <description>Placebo Comparator - group received placebo 3 times daily. *Both groups received Morphine as needed.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Gabapentin/Morphine</title>
          <description>Gabapentin - group received gabapentin 3 times daily 5 mg/kg/dose. *Both groups received Morphine as needed.</description>
        </group>
        <group group_id="B2">
          <title>Placebo/Morphine</title>
          <description>Placebo Comparator - group received placebo 3 times daily. *Both groups received Morphine as needed.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="32"/>
            <count group_id="B2" value="31"/>
            <count group_id="B3" value="63"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.8" spread="2.1"/>
                    <measurement group_id="B2" value="14.2" spread="1.8"/>
                    <measurement group_id="B3" value="14.5" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Amount of Morphine Consumed (mg/kg/hr)</title>
        <description>Patients are taken to the PARU immediately after surgery, and typically remain for a period of 1 hour.</description>
        <time_frame>PARU (Postanesthesia Recovery Unit - participants typically remain in PARU for 1 hour)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Gabapentin/Morphine</title>
            <description>Gabapentin - group received gabapentin 3 times daily 5 mg/kg/dose. *Both groups received Morphine as needed.</description>
          </group>
          <group group_id="O2">
            <title>Placebo/Morphine</title>
            <description>Placebo Comparator - group received placebo 3 times daily. *Both groups received Morphine as needed.</description>
          </group>
        </group_list>
        <measure>
          <title>Amount of Morphine Consumed (mg/kg/hr)</title>
          <description>Patients are taken to the PARU immediately after surgery, and typically remain for a period of 1 hour.</description>
          <units>mg/kg/h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.064" spread="0.031"/>
                    <measurement group_id="O2" value="0.044" spread="0.017"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Side Effect Occurrence</title>
        <description>The number of episodes of/occurrence of side effects was monitored in both groups.</description>
        <time_frame>First 10 days after surgery</time_frame>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Amount of Morphine Consumed (mg/kg/hr)</title>
        <time_frame>Day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Gabapentin/Morphine</title>
            <description>Gabapentin - group received gabapentin 3 times daily 5 mg/kg/dose. *Both groups received Morphine as needed.</description>
          </group>
          <group group_id="O2">
            <title>Placebo/Morphine</title>
            <description>Placebo Comparator - group received placebo 3 times daily. *Both groups received Morphine as needed.</description>
          </group>
        </group_list>
        <measure>
          <title>Amount of Morphine Consumed (mg/kg/hr)</title>
          <units>mg/kg/h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.055" spread="0.017"/>
                    <measurement group_id="O2" value="0.046" spread="0.016"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Amount of Morphine Consumed (mg/kg/hr)</title>
        <time_frame>Day 2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Gabapentin/Morphine</title>
            <description>Gabapentin - group received gabapentin 3 times daily 5 mg/kg/dose. *Both groups received Morphine as needed.</description>
          </group>
          <group group_id="O2">
            <title>Placebo/Morphine</title>
            <description>Placebo Comparator - group received placebo 3 times daily. *Both groups received Morphine as needed.</description>
          </group>
        </group_list>
        <measure>
          <title>Amount of Morphine Consumed (mg/kg/hr)</title>
          <units>mg/kg/h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.047" spread="0.019"/>
                    <measurement group_id="O2" value="0.036" spread="0.016"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Gabapentin/Morphine</title>
          <description>Gabapentin - group received gabapentin 3 times daily 5 mg/kg/dose. *Both groups received Morphine as needed.</description>
        </group>
        <group group_id="E2">
          <title>Placebo/Morphine</title>
          <description>Placebo Comparator - group received placebo 3 times daily. *Both groups received Morphine as needed.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Lynn Rusy, MD</name_or_title>
      <organization>Medical College of Wisconsin</organization>
      <phone>414-266-2555</phone>
      <email>lrusy@chw.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

